Stock ARGX ARGENX SE
Add to a list
To use this feature you must be a member
Log inSign up

argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Real-time Euronext Bruxelles
Other stock markets
 13:56:27 16/07/2024 BST 		5-day change 1st Jan Change
431.5 EUR +1.17% Intraday chart for argenx SE +3.73% +25.62%
02:29pm Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Big Bank Earnings Roll in Amid Rising Hopes of Rate Cuts MT
10:59am Argenx, Zai Lab Win Chinese Nod for Injectable Formula of Autoimmune Disorder Drug MT
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about argenx SE

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Big Bank Earnings Roll in Amid Rising Hopes of Rate Cuts MT
Argenx, Zai Lab Win Chinese Nod for Injectable Formula of Autoimmune Disorder Drug MT
Argenx, Zai Lab Get Chinese Regulator's Nod for Subcutaneous Add-on Injection Targeting Eneralized Myasthenia Gravis MT
Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China CI
European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading MT
Evercore ISI Raises Price Target on argenx to $533 From $478, Maintains Outperform Rating MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Lexeo Therapeutics, Inc. Appoints Tim Van Hauwermeiren to Its Board of Directors CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
HC Wainwright Raises Argenx's Price Target to $490 From $448, Maintains Buy Rating MT
Truist Securities Raises Argenx's Price Target to $480 From $440, Buy Rating Maintained MT
Scotiabank Raises Argenx's Price Target to $416 From $408, Sector Perform Rating Maintained MT
Goldman Sachs Raises Argenx's Price Target to $506 From $484, Buy Rating Maintained MT
Citigroup Raises Argenx's Price Target to $512 From $463, Buy Rating Maintained MT
European shares start the week higher on autos, banks RE
Argenx Shares Rise Following Vyvgart Hytrulo Approval MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading MT
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm... Our Logo
BofA Securities Raises Argenx Price Target to $607 From $535, Maintains Buy Rating MT
Stifel Raises Argenx Price Target to $500 From $485, Maintains Buy Rating MT
Sector Update: Health Care Stocks Advance Premarket Monday MT
Piper Sandler Adjusts argenx Price Target to $535 From $522, Maintains Overweight Rating MT
Wells Fargo Adjusts argenx Price Target to $542 From $478, Maintains Overweight Rating MT
Evercore ISI Raises Price Target on argenx to $478 From $437, Keeps Outperform Rating MT
Argenx Says FDA Approved Vyvgart Hytrulo for Treatment of Neuromuscular Disorder MT

Chart argenx SE

Chart argenx SE
More charts

Company Profile

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Sector
Biotechnology & Medical Research
Calendar
01:30pm - R&D Day
Related indices
STOXX EUROPE 600 (EUR) , BEL-20
More about the company

Income Statement Evolution

More financial data

Ratings for argenx SE

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
426.5 EUR
Average target price
459.4 EUR
Spread / Average Target
+7.71%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ARGENX SE Stock argenx SE
+25.62% 27.67B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.63% 127B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+23.21% 117B
BIONTECH SE Stock BioNTech SE
-20.17% 20.33B
GENMAB A/S Stock Genmab A/S
-16.77% 16.79B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.07% 15.63B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.92% 14.84B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.70% 14.65B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+58.32% 14.43B
INSMED INCORPORATED Stock Insmed Incorporated
+149.98% 12.49B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ARGX Stock
  4. News argenx SE
  5. Argenx, Zai Lab Get Chinese Regulator's Nod for Subcutaneous Add-on Injection Targeting Eneralized Myasthenia Gravis